Navigation Links
Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round
Date:11/18/2014

SAN DIEGO, Nov. 18, 2014 /PRNewswire-USNewswire/ -- Renova Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, announced that Daniel M. Bradbury joined its board of directors. The company also completed its third round of funding, raising $7.52 million.

New board member brings decades of life science experience

Mr. Bradbury is a life sciences executive with more than 30 years of experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. He is Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm, and the former President and Chief Executive Officer of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases.

"I am excited to join the Renova Therapeutics board," said Mr. Bradbury. "The company's gene therapy work is transformational, and their potential for success is great.  Renova is poised to help millions of people suffering from congestive heart failure by positively impacting patient outcomes."

Mr. Bradbury was CEO of Amylin, which was listed on the Nasdaq 100, from March 2007 until Bristol-Myers Squibb acquired the company for $7 billion in August 2012. During Mr. Bradbury's 18 years at the company, Amylin launched the first once-a-week diabetes therapy and three other first-in-class medicines.

Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. He joins the following directors of the Renova Therapeutics board:

Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics
Roy Cosan, President of Renova Therapeutics
H. Kirk Hammond, MD, Professor of Medicine, University of California, San Diego, and Co-founder of Renova Therapeutics
Craig Andrews, COO, Co-founder and Secretary of Renova Therapeutics
Andy Noorda, Managing Member of The Canopy Group
Michael Torres, CEO of Adelante Capital Management

Company now funded through 2016

Renova Therapeutics completed its third round of funding on Sept. 30, 2014, raising $7.52 million through a Series C Preferred Stock financing round. Investments in the company have come primarily from high net-worth individuals. The company is funded through 2016.

About Renova Therapeutics

There are more than 32 deaths per hour from congestive heart failure in the United States. Renova Therapeutics is working to change that.

Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases. CHF is the most rapidly growing cardiovascular disorder in the United States, with an estimated six million people afflicted and 550,000 new cases diagnosed every year. Approximately 26 million patients have CHF worldwide. Renova Therapeutics, in a Public-Private Partnership with the National Institutes of Health, is currently supporting a Phase I/II trial of its novel lead therapy for patients with severe CHF (Class II, III and IV). This initial product is a single-dose gene therapy that, in animal studies, has shown substantially improved, sustained outcomes in heart failure models by safely and significantly improving myocardial function. The product is being evaluated for its safety and initial efficacy in a 3:1 randomized, double-blinded, placebo-controlled dose-ranging study involving 56 patients across seven US medical centers. The company's product pipeline also includes a second-generation therapy for CHF patients and a groundbreaking therapy in pre-clinical stage for sufferers of Type II diabetes. Renova Therapeutics was founded in 2009 and is led by an experienced management team that co-founded the first publicly traded cardiovascular gene therapy company, Collateral Therapeutics.

Photo - http://photos.prnewswire.com/prnh/20141117/159100


'/>"/>
SOURCE Renova Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2019)... ... November 14, 2019 , ... ... a Band-Aid that will measure a baby’s blood oxygen levels, a vital indication ... supply. Unlike current systems used in hospitals, this miniaturized wearable device will be ...
(Date:11/14/2019)... TAMPA, Fla. (PRWEB) , ... November 14, 2019 , ... ... research and patient services in Tampa Bay at the 7th Annual Treasure Chests 5K ... put on by the Tampa Bay Buccaneers and powered by Jabil. , “We ...
(Date:11/12/2019)... WASHINGTON (PRWEB) , ... November 12, 2019 , ... ... manufacturers of vinyl, vinyl chloride monomer (VCM), additives, and modifiers, announced recipients of ... the vinyl industry for improving worker safety and protecting the environment at manufacturing ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... ... Early praise for A Nurse’s Step-by-Step Guide to Publishing a Dissertation or DNP ... insight and vital guidance for publishing dissertations or DNP projects. A Nurse’s Step-by-Step Guide ... bookshelf and will be shared with new graduates and colleagues alike.” , -Nancy ...
(Date:11/11/2019)... ... November 11, 2019 , ... Thermal Product Solutions, a global ... Depyrogenation Sterilizers to the Pharmaceutical Industry. The units will be used for ... with work chamber dimensions of 36” W x 36” D x 53” H. ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... improved foodborne illness prevention and urges increased adoption of compliance technology in the ... of vegetable products sold to select retailers in the United States and Canada ...
(Date:11/9/2019)... ... November 08, 2019 , ... The Women’s Dermatologic Society (WDS) announced ... concerns. The WDS Board of Directors appointed Molly Hinshaw, MD to fill the remainder ... March 2019-March 2020 term and will be presented to the membership as the 2020-2021 ...
(Date:11/9/2019)... YORK (PRWEB) , ... November 09, 2019 , ... On ... the story of a retired and disabled 64-year-old New Yorker who recently faced homelessness. ... moved her into transitional housing until she found a new home in an assisted-living ...
Breaking Medicine News(10 mins):